植物源性化合物在结直肠癌 (CRC) 中的分子理解和药理学效力:批判性分析和未来展望。
Molecular Understanding and Pharmacological Potency of Plant-Derived Compounds in Colorectal Cancer (CRC): A Critical Analysis and Future Perspectives.
发表日期:2024 Jul 04
作者:
Vaagdevi Mukkavilli, Gnanasekaran Ramakrishnan, Koteswara Reddy Gujjula, Balachandran S, Sahiti Chamarthy, Janaki Ramaiah Mekala
来源:
Epigenetics & Chromatin
摘要:
结直肠癌 (CRC) 是死亡的主要原因,也是第三大最常确定的恶性肿瘤。尽管检测和治疗方面取得了进步,结直肠癌(CRC)仍然是癌症相关发病率和死亡率的最大驱动因素。现代习惯和饮食疏忽可能是癌症患病率增加的原因之一。因此,饮食习惯的改变将会产生更好的影响,并有助于找到更好的结直肠癌治疗方法。最初,CRC 被视为一种遗传事件,目前,研究重点是 CRC 细胞中染色质和 microRNA (miRNA) 的表观遗传修饰。人们从遗传、表观遗传和 miRNA 修饰的角度对姜黄素、白藜芦醇、类黄酮和鞣花单宁等天然产物进行了探索,这些化合物将具有未来的治疗作用。此外,这些关键参与者及其类似物的提取物将干预涉及癌症增殖、细胞凋亡、细胞周期停滞以及表观遗传和 miRNA 修饰的信号通路激活。这些 miRNA 的调节以及全局修饰可能会对 CRC 进展和癌症肿瘤细胞敏感性产生影响。© 2024。作者获得 Springer Science Business Media, LLC(Springer Nature 旗下子公司)的独家许可。
Colorectal cancer (CRC) is the main driver of fatality and the 3rd most often determined malignancy. Despite advances in detection and therapy, colorectal cancer (CRC) endures as the largest driver of cancer-related morbidity, and mortality. Modern habits and dietary negligence might be one of the reasons that have enhanced cancer prevalence. Thus, changes in Dietary habits will have a better impact, and help in finding a better cure for CRC. Initially, CRC was explored as a genetic event and currently, the research is focused on the epigenetic modifications of chromatin and microRNA (miRNA) in CRC cells. Natural products such as Curcumin, Resveratrol, Flavonoids, and Ellagitannins are been explored as compounds from the perspective of genetic, epigenetic, and miRNA modifications which will have future therapeutic aspects. Also, the extracts of these key players and their analogs will intervene the signaling pathway activation that involves in cancer propagation, apoptosis, cell cycle arrest, and epigenetic and miRNA modifications. Modulations of these miRNAs, and modification globally might have impact on CRC progression, and cancer tumor cell sensitivity.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.